{
    "company_name": "OPTHEA LIMITED",
    "address": "Suite 0403, Level 4, 650 Chapel Street, SOUTH YARRA, VIC, AUSTRALIA, 3141",
    "summary": "Opthea is a drug development company developing innovative, biologics-based therapies for the treatment of eye disease.",
    "details": "Opthea is a drug development company developing innovative, biologics-based therapies for the treatment of eye disease.",
    "website": "http://www.opthea.com",
    "stock_code": "OPT",
    "links": "['#main-content', '#main-content', 'https://ir.opthea.com/resources/investor-email-alerts', '/', 'https://www.linkedin.com/company/opthea', 'https://twitter.com/OptheaLimited', '/', 'https://opthea.com/company/', 'https://opthea.com/science/', 'https://opthea.com/clinical-trials/', '/clinical-trials/#overview', '/clinical-trials/#phase-3', '/clinical-trials/#phase-2', '/clinical-trials/#phase-1', '/clinical-trials/#dme', '/clinical-trials/#pcv', 'https://ir.opthea.com', 'https://ir.opthea.com/press-releases/', 'https://ir.opthea.com/resources/contact-us/', '#about', 'https://lifescievents.com/event/opthea', '#about', '/company/', '/science/', '/clinical-trials/#phase3-ranibizumab', '/clinical-trials/#phase3-aflibercept', '/clinical-trials/#phase2b-ranibizumab', '/clinical-trials/#phase1-ranibizumab', '/clinical-trials/#phase1-aflibercept', '/clinical-trials/#phase3-ranibizumab', '/clinical-trials/#phase3-aflibercept', '/clinical-trials/#phase2b-ranibizumab', '/clinical-trials/#phase1-ranibizumab', '/clinical-trials/#phase1-aflibercept', '/clinical-trials/', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-appoints-john-han-pharmd-vp-medical-affairs-0', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-appoints-john-han-pharmd-vp-medical-affairs-0', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-participate-23r-annual-needham-virtual-healthcare', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-participate-23r-annual-needham-virtual-healthcare', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-appoints-sujal-shah-board-directors', 'https://opthealimited.gcs-web.com/news-releases/news-release-details/opthea-appoints-sujal-shah-board-directors', 'https://ir.opthea.com/press-releases/', 'https://ir.opthea.com/corporate-presentation', 'https://ir.opthea.com/events-presentations', 'https://ir.opthea.com/in-the-media', 'https://ir.opthea.com/sec-filings', 'https://ir.opthea.com/annual-half-year-reports', 'https://ir.opthea.com', 'https://ir.opthea.com/resources/contact-us', 'https://ir.opthea.com/resources/investor-email-alerts', 'https://lifescievents.com/event/opthea', '/company/#mission', '/company/#overview', '/company/#history', '/company/#management-team', '/company/#board-of-directors', '/company/#clinical-advisory-board', '/science/#vision', '/science/#opportunity', '/science/#technology', '/science/#overview', '/clinical-trials/#phase-3', '/clinical-trials/#phase-2', '/clinical-trials/#phase-1', '/clinical-trials/#dme', '/clinical-trials/#pcv', 'https://ir.opthea.com/', 'https://ir.opthea.com/press-releases', 'https://ir.opthea.com/in-the-media', 'https://ir.opthea.com/events-presentations', 'https://ir.opthea.com/sec-filings', 'https://ir.opthea.com/annual-half-year-reports', 'https://ir.opthea.com/press-releases', 'https://ir.opthea.com/resources/contact-us', 'https://www.linkedin.com/company/opthea', 'https://twitter.com/OptheaLimited', '/privacy-policy', '/terms-of-use', '/cookie-notice/', '/privacy-policy', '/terms-of-use', '/cookie-policy/']",
    "images": "https://opthea.com/wp-content/themes/opthea-2023/images/back-to-top-button@2x.png, https://opthea.com/wp-content/uploads/2022/12/icon-search.png, https://opthea.com/wp-content/uploads/2022/12/icon-linkedin.png, https://opthea.com/wp-content/uploads/2022/12/icon-twitter.png, https://opthea.com/wp-content/uploads/2022/12/logo.png, https://opthea.com/wp-content/uploads/2024/04/event-WEBCAST-w-button-and-border.png, https://opthea.com/wp-content/uploads/2023/04/stats-red-circle.png, https://opthea.com/wp-content/uploads/2023/04/stats-green-circle.png, https://opthea.com/wp-content/uploads/2023/04/stats-blue-circle.png, https://opthea.com/wp-content/uploads/2023/04/stats-navy-circle.png, https://opthea.com/wp-content/uploads/2023/04/science-infographic-v4.png, https://opthea.com/wp-content/uploads/2023/03/clinical-trials-phases-home-v3.png, https://opthea.com/wp-content/uploads/2023/03/clinical-trials-phases-home-mobile-v3.png, https://opthea.com/wp-content/uploads/2022/12/announcements-icon.png, https://opthea.com/wp-content/uploads/2023/04/presentation-icon.png, https://opthea.com/wp-content/uploads/2023/04/media-icon@2x-298x300.png, https://opthea.com/wp-content/uploads/2023/04/sec-icon@2x.png, https://opthea.com/wp-content/uploads/2023/04/reports-icon@2x-300x300.png, https://opthea.com/wp-content/uploads/2022/12/connect-icon.png, https://opthea.com/wp-content/uploads/2022/12/newsletter-icon.png, https://opthea.com/wp-content/uploads/2024/03/life-sciences-event-pop-up-banner.jpg, https://opthea.com/wp-content/uploads/2022/12/logo.png, https://opthea.com/wp-content/uploads/2023/03/icon-linkedin@2x.png, https://opthea.com/wp-content/uploads/2023/03/icon-twitter@2x.png",
    "company_logo_link": "https://opthea.com/wp-content/uploads/2022/12/logo.png"
}